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1. Introduction 
Polyunsaturated fatty acids and their metabolites are crucial to the physiologic and 
pathophysiologic processes in inflammation. The balance between n-6 and n-3 
polyunsaturated fatty acids in body tissues is a key to regulating the inflammatory reaction 
and preventing exacerbated inflammation in inflammatory disorders. Altering fatty acid 
type and their composition in phospholipids through diet supplements for beneficial 
outcomes in disease has been of major interest to the community. The sources of 
polysaturated fatty acid include de novo synthesis, essential fatty acids obtained from the 
diet, elongation and desaturation to obtain fatty acids of longer chain length by tissues.  
The types of fatty acids being esterified in membrane phospholipids provide a characteristic 
fatty acid composition of the phospholipids which can dictate the characteristics of the 
inflammatory response depending on the types of metabolites of polyunsaturated fatty 
acids formed through the lipoxygenase (LOX) and cyclooxygenase (COX) pathways, either 
promoting or inhibiting the inflammatory process, by controlling intracellular signalling 
pathways, such as PKC, MAP kinases, PI3 kinase etc 
While focusing on the use of n-3 polyunsaturated fatty acids in treating rheumatoid 
arthritis, cardiovascular diseases and asthma, it is highlighted that such treatments are at a 
‘cross road’ because of poor understanding of the field of lipidomics and in 
supplementation approaches in those with various illnesses, including inflammatory 
diseases. 
2. Sources of arachidonic acid and other fatty acids 
Fatty acids in the body can be obtained by de novo synthesis in tissues, through the diet or 
from the hydrolysis of membrane phospholipids. Human beings can synthesize fatty acids 
up to 16:0 (palmitate) de novo from acetyl coenzyme, by a series of cycles of sequential 
condensation, reduction, dehydration and reduction. The chain is elongated by two carbon 
atoms per cycle. 16:0 is then elongated to 18:0 (stearate) and desaturated to yield 18:1n-9 
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(oleate). Alternatively, 16:0 is desaturated to 16:1n-9 (palmitoleate) and elongated to 18:1n-9. 
A variety of longer chain fatty acids can be derived from 18:1n-9 by a combination of 
elongation and desaturation reactions. However, mammalian cells are unable to perform 
these reactions because they do not express the enzymes, 12 and 15 desaturases to 
introduce double bonds at carbon atoms beyond C-9. Consequently, mammalian cells 
cannot synthesise 18:2n-6 (linoleic) and 18:3n-3 (α-linolenate). These fatty acids, required by 
the animal but cannot be synthesised endogenously, are therefore considered as essential 
fatty acids and are obtained from the diet. The essential fatty acids serve as starting points 
for the synthesis of longer chain fatty acids such as 20:4n-6 (arachidonic acid, AA) and the n-
3 fatty acids 20:5n-3 (eicosapentaenoic acid, EPA) and 22:6n-3 (docosahexaenoic acid, DHA)  
by elongation and desaturation through the action of elongases and desaturases (e.g 6, 5 
and 4). AA is derived from 18:2n-6 while EPA and DHA are derived from 18:3n-3. 
Dietary fatty acids can be obtained from animal meats, fish, green vegetables, and from oils 
derived from the above. They mainly occur as triacylglycerols. Essential fatty acids are 
found in abundance in green leafy vegetables and the seeds of most plants. The n-3 fatty 
acids EPA and DHA are abundant in marine oils and fish rich diets are another source of 
these fatty acids. Grain-fed animals are rich in AA (Simopoulos, 1991). 
3. Transport and uptake of fatty acids 
Following absorption by the intestine, the fatty acids are transported to tissues where they 
may be utilized immediately or stored. At least four types of vehicles have been shown to be 
involved in their transportation: (i) chylomicrons, where dietary triacylglycerol is carried in 
protein-coated lipid droplets and transported to the whole body from the intestine; (ii) 
ketone bodies (acetoacetate and -hydroxybutyrate) and (iii) very low density lipoprotein 
(VLDL), which are responsible for transporting fatty acids, processed by or synthesised in 
the liver, to either adipose tissue for storage, or to various tissues to be used for cell 
structure and metabolism and (iv) as non-esterified fatty acid. Triacylglycerol in the blood is 
enzymatically hydrolysed by lipases, such as lipoprotein lipases, on the surface of 
endothelial cells. The released free fatty acids become bound to serum fatty acid binding 
protein eg. albumin, type IV fatty acid transporter, which carries the released fatty acids in 
the blood stream to appropriate tissue sites. The free fatty acids in the extracellular fluid 
continuously exchange with the intracellular fatty acids which are released by the action of 
phospholipase A2. This process is called intracellular fatty acid turnover (McGarry, 1993). 
How fatty acids are taken up by cells remains unclear. It has been proposed that fatty acids 
firstly become dissociated from albumin and then bind to a fatty acid transporter protein in 
the plasma membrane or a flip flop mechanism. A fatty acid translocase (FAT) with 
homology to CD36 has also been reported to be involved in the transport of long chain fatty 
acids (Bonen et al, 2002). There is evidence that fatty acids can also enter cells by a flip flop 
mechanism (Kamp et al, 2003). These two modes of fatty acid uptake need not be mutually 
exclusive. Once inside the cell, fatty acids are transported to various intracellular sites by the 
cytosolic fatty acid binding protein (FABP, 14-15 kDa) where they interact with appropriate 
proteins/structures to evoke cellular responses (Spector, 1992; Poirrier et al, 1996). The 
precise mechanism by which fatty acids are taken up by neutrophils is still poorly defined. 
However, it has been demonstrated that the ability of a fatty acid to partition into the 
neutrophil plasma membrane is not sufficient to evoke superoxide production (Steinbeck et 
al, 1991). Similarly, the observation that saturated fatty acids (lacking biological actions) 
have a greater ability to partition into the plasma membrane of cytotoxic T lymphocyte than 
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cis unsaturated fatty acids, is inconsistent with their biological activity being totally caused 
by membrane partitioning of a fatty acid (Anel et al, 1993). 
4. Arachidonic acid and its metabolites are central to the development of 
inflammatory reactions  
AA is an important promoter of physiologic processes of body tissue and organs. AA and its 
metabolites can act as an intercellular signalling molecule as well as intracellular secondary 
signalling molecule  (Ferrante et al. 2005). The role of this fatty acid and its products in 
autoimmune and allergic inflammation has also been abundantly described and 
appreciated, such that AA and pathways involved in its metabolism have been the targets of 
medications. The resolution of inflammation initiated through the release of AA from 
cellular membrane phospholipids is important and where its generation persists, this 
reaction evolves into a chronic and debilitating condition. The main pathways for its 
metabolism have been the lipoxygenase (LOX) and cyclooxygenase (COX) enzymes. 
AA and its metabolites can be generated at several cellular points. Apart from production at 
local tissues, be these immune cells or barrier cells such as endothelial cells, epithelial cells 
etc, the infiltrating cells, particular leukocytes, provide a rich source of these mediators of 
inflammation. Thus it is not surprising that the lipids influence several key functions of 
leukocytes which include, chemotaxis, oxygen radical generation, granule enzyme release 
and cytokine production (Ferrante et al, 2005). 
AA may control inflammation through several activities. AA per se has been shown to cause 
cellular activation independently of its metabolism via the LOX and COX pathways 
(Ferrante et al, 2005). The generation of several metabolites such as LTB4 and PGE2 gives the 
system a potent inflammatory potential. 
5. Release of AA from the cellular phospholipid pools and the generation of 
eicosanoids  
Cellular activation leads to the activation of Phospholipase A2 (PLA2) and the release of 
AA from the sn-2 position of the phospholipids (Balsinde et al, 2002). This activation can 
be brought about by many different types of agonists acting usually via a cell surface 
receptor. This includes intercellular signalling molecules such as cytokines which are 
involved in inflammatory responses in both the context of physiologic and 
pathophysiologic states.  
Amongst the various structurally different forms of the PLA2 is the cytosolic (cPLA2α, 
Group IVA), believed to play an important role in eicosanoids production (Kita et al, 2006; 
Ghosh et al, 2006). Submicromolar concentrations of Ca++ promotes the translocation of 
cPLA2 from the cytosol to the perinuclear membrane where it becomes activated by MAP 
kinases (Lin et al, 1993; Nemenoff et al, 1993). There it causes preferential hydrolysis of AA-
containing phospholipids, releasing AA to become available to downstream enzymes 
including LOX and COX, important in production of leukotrienes and prostaglandins (Fig 
1). Its importance has been concluded from studies showing that mice deficient in 
cPLA2were not susceptible to allergy induced brocho-constriction, airway hyper-
responsiveness, as well as adult respiratory distress syndrome (Wu et al, 2010). Mice 
deficient in cPLA2α were also protected from experimental autoimmune encephalomyelitis 
(Marusic et al, 1995). 
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Fig. 1. Outline of the metabolism of arachidonic acid, eicosapentaenoic acid and 
docosahexaenoic acid by the lipoxygenases and cyclooxygenases. LOX, lipoxygenase; COX, 
cyclooxygenase; HPETE, hydroperoxyeicosatetraenoic acid; HPEPE, 
hydroperoxypentaenoic acid; HETE, hydroxyeicosatetraenoic acid; HEPE, 
hydroxypentaenoic acid; LT, leukotrienes; TX, thromboxane; PG, prostaglandin; LX, lipoxin; 
HpDHA, hydroperoxyDHA. 
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Cell activation leads to the generation of AA-derived eicosanoids (Fig 1). The main ones  are 
divided into three groups, leukotrienes (LTs), prostaglandins (PGs) and lipoxins (LXs). Their 
biological properties give rise to a regulatory network of inflammation, having both an 
effect on cells of the immune system, macrophages, T cells, neutrophils as well as non-
immune cells such as endothelial cells. While the metabolism of AA via the LOX and COX 
pathways is considered to be inflammatory, it is also evident that some products may 
exhibit anti-inflammatory properties. 
It is clear from several studies that different eicosanoids are generated at different times of 
an acute inflammatory response (Serhan, 2005; Serhan et al, 2008). Hence, prostaglandins 
and leukotrienes are rapidly generated, whereas the lipoxins, also produced from AA, are 
generated later with the onset of the resolution phase. During acute inflammation, activation 
of cPLA2 results in the conversion of the released AA by 5-LOX and COX to leukotrienes 
such as LTB4, a potent neutrophil activator and chemoattractant, and proinflammatory 
prostaglandins which control local blood flow, vascular dilation and permeability changes 
needed for leukocyte adhesion, diapedesis, and recruitment. The prostaglandins initiate a 
number of responses relevant in inflammation (i.e., vasoconstriction, vascular permeability 
changes, pain, vasodilation and edema). However, the production of prostaglandins such as 
PGE2 and PGD2 which possess proinflammatory properties, also signals the end of the 
inflammatory response by activating the transcriptional regulation of 15-LOX in neutrophils 
that initiates an eicosanoid class switch from a proinflammatory profile to a resolving 
profile, including the generation of EPA- and DHA-derived resolvins and/or protectins. In 
murine models, resolution of acute inflammation is accompanied by the appearance in 
exudates of EPA and DHA, which follows the appearance of non-esterified AA. Indeed, 
leukotrienes (potent chemoattractants) are deactivated and the transcriptional regulation of 
enzymes required for LX and resolvin production is activated. (Serhan, 2005; Serhan et al, 
2008). The combined actions of 5-LOX, 12-LOX and 15-LOX lead to the generation of 
lipoxins such as LTA4, resolvins and/or protectins. These mediators have anti-inflammatory 
and pro-resolving activities.  
6. Biological properties of eicosanoids 
The cellular actions of the LTB4 and cysteinyl leukotrienes (cysLTs), LTC4, LTD4 and 
LTE4, occur through their binding to specific G protein-coupled receptors found on 
responsive tissues e.g., smooth muscle and inflammatory cells of the immune system 
e.g., neutrophils. The distribution of receptors for LTs on various cell types are 
summarised in Table 1 (Okunishi et al, 2011). Two receptors for cysLTs have been well 
characterised, CysLt1 and CysLt2. LTD4 has high affinity and LTE4 has low affinity for 
these receptors. But other receptors are being recognised for CysLTs which includes a 
specific receptor for LTE4 (Maekawa et al, 2008). 
LTB4 has two receptors, a high affinity, BLT1 and lower affinity, BLT2 (Yokomizo et al, 
2000). Notably BLT1 is expressed predominantly on leukocytes (Table 1). The biological role 
of BLT2 requires further studies. LTB4 is recognised for its potent chemoattractant properties 
for neutrophils. It also activates other neutrophil responses such as respiratory burst 
(oxygen radical production) and degranulation. As indicated by the expression of BLT1 on 
other leukocytes, apart from neutrophils (Table 1), LTB4 activates also macrophages, 
eosinophils, T cells and dendritic cells (DCs). 
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Cell-type BLT1 CysLT1 CysLT2 
Macrophages  + ±# ± 
Dendritic cells + + ? 
B cells ? + ? 
CD4 + T cells + + ? 
CD8 + T cells + ?# ? 
Neutrophils + + + 
Eosinophils + + + 
Basophils + + + 
Mast Cells + + + 
Airway smooth muscle cells + + ? 
Endothelial cells + + + 
Table 1. Leukotriene receptor expression. (+), positive; (+), negligible; (?), not determined; 
(#) up-regulation upon cell activation (adapted from Okunishi et al, 2011) 
The action of PGs is through the rhodopsin-like 7-transmembrane-spanning G protein-
coupled receptors. These prostanoid receptors subfamily consists of 8 members 
EP1/EP2/EP3/EP4 bind PGE2, DP/CRTH2 bind PGD2, FP binds PGF2α, IP binds PGI2, TP 
binds TXA2 (Table 2). The CRTH2 receptor is expressed on Th2 lymphocytes and a member 
of the fMLF receptor superfamily (Ricciotti and FitzGerald, 2011).  
7. Eicosanoids and inflammation 
7.1 Leukotrienes 
Inflammation, whether physiologic or pathophysiologic, is manifested by the accumulation 
of leukocytes and plasma leakage into the tissue site. The leukotrienes form a major family 
of the inflammatory mediators generated which significantly contributes to the process. 
LTB4 through its chemotactic properties for several cell types including neutrophils and T 
cells, causes infiltration and accumulation of leukocytes at inflammatory foci. LTB4 increases 
vascular permeability of post capillary venules. The ability of LTs to activate DCs has 
indicated a role in antigen presentation and T cell sensitisation. Relevant to this action is the 
finding that LTs are produced through the innate immune response, where the various 
pattern recognition receptors (e.g., Toll-like receptors, TLRs) are expressed on different cell 
types (Alvarez et al, 2010). Thus LTs may play important roles in the adaptive immune 
response at an early phase. 
 
Prostaglandin 
Class Receptor subtype Type of cells/tissues 
PGE2 EP1, EP2, EP3, EP4 Brain, kidneys, VSMCs, platelets
PGD2 DP, CRTH2 Mast cells, brain, airways, Th2 lymphocytes 
PGF2a FPA, FPB Uterus, airways, VSMCs, eyes
PGI2 IP-IP, IP-TPa Endothelium, VSMCs, platelets, kidney, brain 
TxA2 TPa, TPb Platelets, VSMCs, macrophages, kidney 
Table 2. Expression of prostanoid receptors (adapted from Ricciotti and FitzGerald, 2011). 
VSMC ; vascular smooth muscle cells 
The role of LTs has been established as a key mediator in several inflammatory diseases, 
both in experimental and clinical settings. This includes asthma and allergic rhinitis (Dahlen, 
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2006; Peter-Golden & Henderson, 2007). Their importance extends to the pathophysiology of 
atherosclerosis and progression of cancer. 
7.2 Prostaglandins 
PGE2 is involved in all the signs of inflammation; redness, swelling and pain (Ricciotti & 
Fitzgerald, 2011), through its effects on arterial dilation, increased permeability of the 
microvasculature, peripheral sensory nervous and central sites within the spinal cord and 
brain. PGE2 acts via one of its receptors, EP1 to EP4. Using KO mice deficient in these 
receptors, it has been appreciated that they play important roles in hyperalgesia (PGE2-EP1), 
paw swelling in collagen-induced arthritis (EP2, EP4), Carrageenan-induced paw 
oedema/pleurisy (EP2, EP3), IL-6 production and joint destruction in RA and anti-
inflammatory effects of PGE2 as seen in allergic inflammation. 
The regulation of various cell types by PGE2 occurs through the expression of different EP 
receptors. PGE2 exerts an anti-inflammatory effect on functions of neutrophils, macrophages 
and natural killer cells, the cell-types which underpin the innate immune response (Harris et 
al. 2002). PGE2 also exerts regulatory actions on macrophages, DCs, T and B cells which may 
manifest itself as either inflammatory or anti-inflammatory actions. Examples are regulation 
of DC cytokine profiles and Th1 or Th2 lymphocyte development (Egan et al, 2004). 
Engagement of  EP4 by PGE2 in DCs and T cells promotes differentiation to Th1 and also 
Th17 lymphocytes (Yao et al, 2009). Other ways that PGE2 regulates the immune response is 
through its role in the development of DCs with a migratory phenotyping to promote 
homing to drain lymph nodes (Kabashima et al, 2003; Legler et al, 2006), as well as 
upregulating the expression of co-stimulatory molecules on these cells (Krause et al, 2009). 
In an anti-inflammatory manner, PGE2 suppresses Th1 cell development, B cell function and 
IgE-driven inflammatory response (Roper et al, 1995; Harris et al, 2002). 
PGI2 has potent vasodilator actions and is known to be important in regulation of 
cardiovascular homeostasis. The eicosanoid is an inhibitor of platelet aggregation, leukocyte 
adhesion and vascular smooth muscle cell proliferation (Gryglewski, 2008; Kawabe et al, 
2010). Mice deficient in receptors for PGI2 show an abrogation of the ability of PGI2 to 
potentiate the bradykinin-induced microvascular permeability and a substantially reduced 
carrageenan-induced paw oedema (Murata et al, 1997). Other actions of PGI2 involving the 
IP receptors is an allergic inflammation where it may suppress the Th2-mediated lung 
inflammation (Jaffar et al, 2002).  
PGD2 has inflammatory and homeostatic properties. Thus while in the brain it regulates 
sleep and various other central nervous activities, it has inflammatory function particularly 
in atropic conditions. The eicosanoid promotes broncho- constriction and airways 
neutrophil infiltration, typical of allergic asthma (Hardy et al, 1984; Emery et al, 1980; 
Fujitani et al, 2002). The DP1 and DP2/CRTH2 receptors bind PGD2 with similar high 
affinity and both are responsible for the pro-inflammatory responses. Effects caused by 
PGD2 are dictated by the differential expression of these receptors in tissues such as the 
expression of DP1 receptors in bronchial epithelium is believed to promote the production 
of cytokines and chemokines which recruit eosinophils and lymphocytes in airway 
inflammation and hyperreactivity associated with asthma (Kabashima & Narumiya, 2003). 
Using mice  deficient in DP1 receptors the role of PGD2 and the receptor in airway 
hyperreactivity and Th2-mediated lung inflammation has been documented in animal 
models (Matsuoka et al. 2000). The use of DP1 antagonists in animal models supports a role 
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for the receptor in antigen-induced microvascular permeability and ovalbumin (OVA)-
induced airway hyperreactivity. Reports have also suggested that the DP2/CRTH2 
receptors contribute to inflammatory reactions by controlling cell traffic and the effect of 
function of leukocytes in which it is expressed, Th2 cells, mast cells and eosinophils. An 
increase in its expression has been shown to be associated with some forms of atopic 
dermatitis. However inflammation in other contexts may be inhibited by PGD2-DP1 
receptor where inhibition of DC migration affects T cell proliferation and cytokine 
production (Hammad et al, 2003).  
TXA2 is highly unstable and its activity is mediated mainly through the TP receptor. Studies 
regarding the role of this receptor in physiologic and pathophysiologic responses show that 
its involved in platelet adhesion and aggregation, activation of endothelial inflammatory 
response and contraction/proliferation of smooth muscle cells (Nakahata, 2008). 
8. Arachidonic acid and metabolites in inflammatory disorders 
AA and its metabolites have been shown to play major roles in the pathogenesis of several 
inflammatory conditions (Table 3). Three inflammatory conditions, asthma, rheumatoid 
arthritis and atherosclerosis, will be used to demonstrate the interest and the importance of 
AA and its metabolites in  such diseases/conditions. 
8.1 Asthma 
Arachidonic acid and eicosanoids have been long recognised to play a key role in asthma 
pathophysiology. The hallmark of this condition is airway inflammation and 
hyperresponsiveness. The importance of the enzyme responsible for releasing AA from 
membrane phospholipids, PLA2 has been established using pharmacological inhibitors and 
more recently genetically modified mice. Bronchoalveolar lavage fluid of asthmatics 
contains increased amounts of secretory phospholipase A2 (sPLA2) and increased activity 
compared to controls (Triggiani et al, 2009; Chilton et al, 1996; Bowton et al, 1997). Particular 
interest has centred on group X sPLA2 as this was responsible for most of the activity 
(Hallstrand et al., 2011). Levels of this sPLA2 correlated with eicosanoid release, severity of 
asthma and airway inflammation (Hallstrand et al., 2011). Further studies have suggested 
that group X sPLA2 functions in asthma pathogenesis through the release of cysLTs which 
are involved in airway inflammation and hyperresponsiveness. Mice genetically deficient in 
group X sPLA2 showed a marked reduction of asthma induced with OVA, manifested as 
decreased interstitial oedema, and the accumulation of eosinophils and T cells into the lung 
(Henderson et al, 2007). The Th2 cytokine levels were also decreased in the deficient mice as 
were the eicosanoids, PGE2, PGD2, LTB4, and cysLTs (LTC4, LTD4, LTE4) (Henderson et al, 
2007). Using knock-in mice with human group X sPLA2, it was demonstrated that this could 
restore the airway inflammation (Henderson et al., 2011). The important role of the high 
affinity LTB4 receptor BLT1 also supports the role of LTs in pathogenesis of asthma 
(Watanabe et al, 2009).  
8.2 Rheumatoid arthritis 
AA derived eicosanoids have been shown to play a major role in the pathogenesis of RA. In 
a murine model of  arthritis, a role for cPLA2α was examined using the inhibitor, 
pyrroxyphine (Tai et al, 2010). There was an increase in cPLA2α activity which correlated 
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with arthritis severity. Both bone destruction and incidence of arthritis was reduced by the 
inhibitor. Such effects correlated also with an inhibition of the production of eicosanoids and 
COX-2 induction. 
The importance of eicosanoids in inflammatory arthritis can also be seen from studies with 
mice which were deficient in either the BLT1 receptor or the low affinity BLT2 receptor. In 
the collagen-induce arthritis model, BLT1 was found to mediate the disease. Thus, BLT1-/- 
mice were completely protected and so were the BLT1-/-/BLT2-/- double knockout mice 
(Shao et al, 2006). Because the BLT1-/- mice were completely protected, the authors were not 
able to determine the contribution of BLT2. This was addressed by Mathis et al (2010) who 
reported that BLT2-/- mice showed reduced incidence and severity of disease in an 
autoantibody-induced arthritis model. Note that while the BLT2 receptor is a low affinity 
receptor for LTB4, it is in fact a high affinity receptor for the COX-1 derived 12(S)-
hydroxyheptadeca-5Z, 8E, 10E-trienoic acid. BTL2 is considered a model target for treating 
this inflammatory condition. 
Prostaglandins levels are elevated in synovial fluid and synovial membranes of RA patients 
and are believed to play a role in fluid extravasations and pain in synovial tissue, as well as 
articular cartilage erosion. COX-2 is present in high and COX-1 in smaller amounts in RA 
synovial tissue. Selective COX-2 inhibitors (e.g. celecoxib, valdecoxib and rofecoxib) have 
been used to treat inflammation in RA patients, although some (e.g. valdecoxib and 
rofecoxib) have been withdrawn owing to increased risk of heart attack and stroke in users 
(James et al, 2007). The presence of the metabolites of AA in RA patients’ synovial fluid has 
been outlined (Grignani et al, 1996). When compared with patients with artherosis 
(degenerative joint disease), the levels of LTB4, LTC4 and 6-keto-PGF1 were significantly 
higher in RA patients. 
8.3 Cardiovascular disease and atheroosclerosis  
The 5-LOX/LT pathway has been implicated in the development of cardiovascular disease 
(CVD) based on studies of human genetic variation (polymorphisms in the genes that code 
for 5-LOX or its activating protein, 5-LO-activating protein (FLAP)) and in animals, leading 
to the hypothesis that this pathway promotes atherosclerosis, abdominal aortic aneurysm, 
and myocardial infarction/reperfusion injury. Much of this is based on the known effects of 
LTs on leucocyte chemotaxis, vascular inflammation and enhanced permeability, and 
subsequent tissue/matrix degeneration. Data from a series of studies that involved genetic 
or pharmacological inhibition of either LT biosynthesis (5-LOX, FLAP, LTA4 hydrolase, 
LTC4 synthase) or the LT receptors, have painted a complex picture of 5-LOX/LT 
participation in cardiovascular disease, which is further complicated by marked differences 
between mice and humans (reviewed by Poeckel and Funk, 2010). Added to this is another 
layer of complexity imposed by the cytokine network specific to a particular pathological 
condition which impacts on the expression level and hence, the contribution of 5-LOX to the 
overall disease state. Nevertheless, current data suggest roles for 5-LOX in the early/acute 
stages of atherosclerosis in mice and humans, but only in the advanced stage of the human 
pathology. Hence, LTB4 and CysLT are likely to play critical roles in the early phase of 
atherosclerosis through their influence on leukocyte recruitment, smooth muscle cell 
proliferation, migration of endothelial cells (properties of LTB4) and inflammatory cell 
recruitment, coronary artery constriction and endothelial cell activation (properties of 
CysLT). In the advanced phase, LTB4 may affect plaque stability, and the expression of other 
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components of the 5-LOX pathway such as BLT1, BLT2, FLAP, LTA4 synthase, CysLT1 and 
CysLT2 are up-regulated (reviewed by Poeckel and Funk, 2010). 
The action of LTs in various stages of atherosclerosis development has been reviewed (Back, 
2009). The role of LTB4 in the lipid retention and modification stage is  seen by the finding 
that targeting BLT1 receptor decreases the accumulation of lipids and the infiltration of 
foam cells. The early development of intimal hyperplasia appears also to be influenced by 
cysLTs and LTB4. Targeting their receptors most likely inhibits intimal hyperplasia with 
respect to endothelial dysfunction. Cys-LTs have been suggested to play a role in both 
endothelium relaxation and constriction. The discovery, that endothelial cells express the BLT1 
receptor during atherosclerosis (Back et al., 2005) has also implicated LTB4 in causing the 
changes on the endothelium. The disease progresses into recruitment of leukocytes in the 
vascular wall and the formation of atherosclerotic plaque. Most likely the macrophages 
continue to be the centre point of this development, through their ability to produce LTs , such 
as LTB4 and exacerbate the inflammation at atherosclerotic lesions. This draws in T cells which 
can stimulate macrophages to generate more LTB4, leading to a vicious cycle, perhaps halted 
by anti-LT treatments (Back, 2008). Upon rupture of the fibrous cap there is exposure to the 
blood elements with the consequences of platelet activation and thrombotic occlusion. To date 
there is only indirect evidence for a role of LTs where it has been shown that 5-LOX is located 
in areas where matrix metalloproteinases are present and which are responsible for rupture. 
Plaque in the coronary cerebral arteries will lead to myocardial ischemia and cerebral 
ischemia, respectively. In myocardial ischemia the role of LTs has been controversial from 
suggestions of a major, no role and even to possibly protective role (Back, 2009; Adamek et al., 
2007). In contrast, in cerebral ischemia, the importance of LTs has been acknowledged. LT 
synthesis inhibitors and  cysLT receptor antagonists limited the damage in animal models. 
9. Omega 3 polyunsaturated fatty acids 
Supplementation with n-3 fatty acids is of interest because of its potential benefits in treating 
a range of human diseases and conditions (Table 3). In particular, it is well appreciated that 
increasing the ratio of n-3 over n-6 polyunsaturated fatty acids in membrane phospholipids 
in patients experiencing inflammation has benefits (Simopoulos, 1991). Thus, fatty acid diet 
manipulations have been used in treating a wide variety of diseases/conditions including 
those which have an autoimmune and allergic base. While the mechanisms governing the 
beneficial effects of certain types of polyunsaturated fatty acids in different types of diseases 
is likely to vary, it is well appreciated that altering the types of polyunsaturated fatty acids 
in diets can modify the immune response. This is thought to be the major mechanism by 
which polyunsaturated fatty acids exert their protective effects in inflammatory and 
autoimmune disorders (Calder, 2010).  
High n-3 fatty acid intake for four months significantly increased the general score and 
sigmoidoscope score of active ulcerative colitis patients compared with a placebo diet 
(Simopoulos, 1991; Greenfield et al., 1993). The effects were maintained for three months 
after the fatty acid treatment was discontinued. In a human gingival inflammation model, 
28-day treatment with EPA and DHA (1.8g/day) markedly reduced the gingival index in 
interdental papilla (Campan et al., 1996). Dietary supplementation with fish oil fatty acids in 
conjunction with conventional treatment (cyclosporin) in psoriasis patients has been shown 
to improve the skin lesions and decrease the nephrotoxicity of cyclosporin (Simopoulos, 
1991). In the treatment of RA, the beneficial effects of fish oil are pronounced and  
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Conditions 
Rheumatoid arthritis 
Atherosclerosis 
Acute coronary events 
Allergic diseases 
Asthma 
Psoriasis 
Inflammatory disease 
Multiple sclerosis 
Systemic lupus erythematosus 
Cystic fibrosis 
Type 1 diabetes 
Chronic obstructive pulmonary disease 
Table 3. Inflammation-based conditions which appear to benefit from n-3 polyunsaturated 
fatty acid or fish oil supplementation (adapted from Calder et al, 2010) 
reproducible in both animal models and in human trials. It has been shown that feeding 
mice with EPA and DHA, reduces the incidence and severity of type II collagen-induced 
experimental arthritis (Leslie et al, 1985). Another study demonstrated that n-3 fatty acids 
given in the form of krill oil or fish oil caused a significant reduction in arthritis score and 
hind paw swelling in a collagen-induced arthritis model (Ierna et al., 2010). Dietary 
supplementation with n-3 polyunsaturated fatty acids in RA patients shows  significant 
relief of joint pain and swelling, and the duration of morning stiffness. This has led to a 
reduction in requirement for nonsteroidal anti-inflammatory drugs (NSAIDs), with some 
patients able to discontinue NSAIDs while receiving n-3 fatty acid supplements (Kremer et 
al., 1995; Sperling, 1991). A recent clinical study of -linolenic acid (GLA, 18:3n-6) dietary 
manipulation in RA patients also showed evidence of the alleviation of disease activity 
(Zurier et al., 1996). Many recent studies have shown that production of 
immunological/inflammatory mediators can also be regulated by polyunsaturated fatty 
acids. Diets rich in n-3 polyunsaturated fatty acids significantly reduce the production of the 
pro-inflammatory cytokines, tumour necrosis factor, interleukin-1 and interleukin-2, as 
well as the lipid mediator, platelet activating factor (Sperling, 1991; Endres, 1989; Williams 
et al., 1996) and this could account for some of their anti-inflammatory properties. However 
it has recently been appreciated, through meta analysis, that the use of these fatty acids in 
the human disease is uncertain (James et al., 2010). These investigators have proposed that 
fish oil may be of benefit in RA because it may overcome the cardiovascular risk of non-
steroidal anti-inflammatory agents. 
Supplementation with n-3 fatty acids also decreases the symptoms of dysmenorrhoea, a 
prostaglandin-mediated condition in adolescents. After a two month treatment with fish oil, 
a significant reduction in the Cox Menstrual Symptom Scale was found compared with a 
placebo diet, probably due to alteration of the prostanoid profile by the high n-3 fatty acid 
intake (Harel et al., 1996; Deutch, 1995). Essential fatty acids play an important role in brain 
and retinal development which mainly occurs during the latter half of pregnancy and the 
postnatal stage. The growth of fetal brain acquires approximately 21g/wk of DHA during 
the last trimester of pregnancy. Fatty acids are transported from the maternal circulation 
across the placenta and fetal blood-brain barrier into the central nervous system. A 
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deficiency of essential fatty acids during pregnancy leads to a reduced level of DHA in the 
newborn, which is related to a reduction in slow-wave sleep and impaired vision in these 
infants. Dietary supplementation of n-3 fatty acids to pregnant women and increasing the 
amount of DHA in infant formula are beneficial for early neurological development and 
improve the visual recognition in preterm and term infants (Gibson et al., 1996; Connor et 
al., 1996; Uauy et al., 1996). It has also been shown that diets rich in n-3 fatty acids can 
prevent premature labor and preeclampsia (Olsen & Secher, 1990). Dietary n-3 fatty acids 
also reduce the severity and frequency of relapses in patients suffering from multiple 
sclerosis (Bates, 1990).  
Recent work has shown that n-3 fatty acid supplements modify allergic disease 
development in young children. A systematic review of reports on the effects of n-3 fatty 
acid supplementation during pregnancy and lactation on the risk of developing childhood 
allergic diseases and asthma, concluded that supplementation during pregnancy but not 
during lactation decreases childhood asthma and allergy (Klemens et al, 2011; Kremmyda et 
al, 2009). Thus, fish oil supplements when given to pregnant women with a history of 
allergic diseases gave rise to significant protection against infant allergy development. This 
was associated with reduced cord blood IL-13 (Klemens et al, 2011). The difference between 
supplementation  during pregnancy versus in infancy and childhood and the development 
of eczema, hay fever and asthma has also been highlighted (Calder et al, 2010). Interestingly 
both the susceptibility and the protection afforded by the n-3 supplements were associated 
with the levels of protein kinase C  (PKC) in cord blood T cells and how those cells mature 
into Th1 and Th2 cytokine pattern producers. Low PKC expression in the cord blood T 
cells of an infant increases the risk of development of allergic diseases in childhood (Prescott 
et al, 2007). In another population study of bronchial inflammation induced by grass pollen 
allergy challenge showed that the ratio of n-3: n-6 fats were significantly lower for the 
asthmatics than in healthy subjects (Kitz et al, 2010). 
Obese adolescents appear to benefit from n-3 fatty acid supplementation, shown to improve 
vascular function and cause a reduction in vascular inflammation (Dangardt et al., 2010). 
Furthermore EPA has been shown to be incorporated into advanced atherosclerotic plaques 
(Cawood et al, 2010). The higher EPA content in the plaque is associated with reduced 
plaque inflammation and increased plaque stability (Cawood et al, 2010, Calder & Yaqoob, 
2010). There was a reduction in foam cells, T cells and expression of metalloproteinases. In 
an animal model of atherosclerosis, employing the apoE-deficient mouse, combination of 
extra virgin oil and fish oil gave rise to protection by a mechanism of anti-thrombotic, anti-
hypertriglyceridemic and anti-oxidant (Eilertsen et al., 2011)  
The long chain, n-3 polyunsaturated fatty acids, EPA and DHA, are also substrates for the 
LOX and COX. It is evident that the metabolites of EPA and DHA display several means by 
which they can contribute to the regulatory network of lipid mediators; by replacing the 
highly inflammatory products of AA; having anti-inflammatory activity per se and 
displaying inflammation resolving abilities by having cell protection activity. The ability of 
the LOX and COX systems to generate fatty acid metabolites with substantially lower 
proinflammatory activity than the AA-derived eicosanoids has provided the basis for 
classical strategies to manipulate the inflammatory reaction. For example, increasing the 
ratio of n-3 to n-6 in membrane phospholipids of leukocytes reduces the production of 
inflammatory eicosanoids in favour of metabolites with markedly reduced or those which 
lack proinflammatory activity. Thus diets which contain high levels of the n-3 fatty acids, 
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EPA and DHA or their precursors have been used as ways of decreasing inflammatory 
reactions and relieving the symptoms of these diseases (Simopoulos, 1991).  
The EPA metabolised through COX and LOX pathways leads to the generation of 3-series 
PGs and TXs, and 5-series LTs (Fig 1). These products have some thousand fold less 
inflammatory activity than the 2-series PGs and 4-series LTs derived from AA. Thus the 
release of EPA from the sn-2 position of the membrane phospholipids will lead to an 
increased production of 3-series PGs and 5-series LTs following cell activation. This is 
believed to be a major mechanism of the beneficial effects of EPA/fish oil supplementation 
of patients with inflammatory diseases such as RA (James et al., 2010). In another 
development in the lipid mediator network, more recent work has characterised the 
generation of another class of inflammation regulators, the aspirin-triggered resolvins. This 
involves COX-2 aspirin triggered metabolism of EPA and further action of the 5-LOX, 
leading to the generation of the E-series resolvins, E1 and E2 (Fig 1) (Serhan et al., 2008). 
These molecules are highly potent in inhibiting neutrophil infiltration and in resolving the 
inflammatory reaction. Aspirin also triggers the generation of the D – series aspirin-
triggered resolvins, RvD1, D2, D3, D4, D5, D6 which are generated from DHA, involving 
COX-2 and the 5-LOX. DHA metabolism via the 15-LOX and other reactions leads to the 
release also of these resolvins (Fig 1). DHA can also be oxidised via the 15-LOX to protectin 
D1. This metabolite inhibits neutrophil and T cell migration, airway inflammation, NF-B 
activation, COX-2 induction and TLR macrophage activation. Protectin D1/neuroprotectin 
D1 is known for its neuroprotective properties (Serhan et al., 2008). It reduces brain ischemia 
and reperfusion injury, kidney ischemic injury and has anti-fibrotic activity. 
10. Concluding remarks 
Polyunsaturated fatty acids play critical roles in physiologic and pathophysiologic processes 
involving the immune system. While these have the ability to alter cellular responses as free 
fatty acids, most interest is on the properties of the array of metabolic products which they 
generate. These form a regulatory network which either down- or up-regulates the 
inflammatory reaction. A major effort continues to be made on the need to achieve an 
appropriate balance of n-6:n-3 fatty acids in tissues. The levels and ratios of these fatty acids 
is considered to regulate immune cell function through an effect on cell membrane fluidity, 
cell membrane structure, the expression of functional cell surface receptors and the types of 
oxidized products formed. Eicosanoid generation appears to be central to the inflammatory 
process by influencing the activities of many cell types, T cells, macrophages, neutrophils, 
eosinophils, DCs, endothelial cells, epithelial cells and smooth muscle cells. The 
characteristics of the inflammatory response is dependent on the concentrations and types 
of eicosanoids generated as well as the types of eicosanoid receptors expressed on the cell, 
which can vary dramatically from cell-type to cell-type. Both exogeneous and endogenous 
stimuli promote the activation of phospholipase A2, the release of the polyunsaturated fatty 
acids from the phopholipids and their metabolism via the LOX and COX pathways. While 
most of the products formed from AA metabolism are highly proinflammatory, a number of 
these can also have a dampening effect on the inflammatory response. However, it is 
evident that the elicitation of a highly pro-inflammatory reaction is offset by the presence of 
n-3 fatty acids, EPA and DHA. These are metabolised into the low inflammatory, 5-series 
LTs and 3-series PGs, and anti-inflammatory products, the E-series resolvins/D-series 
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resolvins and neuroprotective lipids, protectins. Because of the diversity of the array of 
eicosanoids and other fatty acid products generated, there is still much to be discovered on 
how this network of fatty acid metabolites promote and inhibit the inflammatory response. 
The time-dependent production of the different types of eicosanoids during various phases 
of the reaction could explain the types of inflammatory reactions we see, for example 
resolving and not resolving. The free fatty acids and their metabolic products also govern 
the synthesis of inflammatory mediators such as cytokines, which are targets for anti-
inflammatory medications. Current evidence underscores the importance of phospholipase 
A2 and eicosanoids in the pathogenesis of inflammatory conditions, including asthma, 
rheumatoid arthritis and atherosclerosis. In contrast to the view of AA as a promoter of 
inflammation, n-3 fatty acids are considered as an attractive approach for anti-inflammatory 
therapy. However, while there is convincing in vitro data and data from animal models of 
an anti-inflammatory action of n-3 fatty acids in these diseases, results from human studies 
remain unconvincing or at best only small benefits are achieved. This is likely to reflect still 
our poor understanding of the actions of these fats when taken as dietary supplements and 
obviously further and more appropriate clinical trials have been suggested (Fritsche, 2006).  
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